ResearchAndMarkets.com has added a report forecasting pelabresib sales and market size through 2034 across the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom and Japan. Pelabresib is an investigational oral bromodomain and extraterminal (BET) protein inhibitor being evaluated mainly for myelofibrosis, as well as essential thrombocythemia, leukemia, myelodysplastic syndromes and other hematologic malignancies. The report identifies unmet demand for more effective frontline myelofibrosis treatment beyond JAK inhibitor monotherapy. In the Phase III MANIFEST-2 study of 430 JAK inhibitor-naive patients, 65.9% of those receiving pelabresib with ruxolitinib achieved at least a 35% reduction in spleen volume at Week 24, compared with 35.2% receiving placebo with ruxolitinib. The primary endpoint was statistically significant, while the overall total symptom score endpoint was not; improvements were reported in predefined intermediate-risk groups. Clinical findings also indicated potential benefits in anemia, hemoglobin response, transfusion requirements and bone marrow fibrosis, with a safety profile consistent with the individual therapies and no unexpected safety signals reported. Novartis acquired pelabresib through its February 2024 agreement to acquire MorphoSys AG. Pelabresib remains investigational and has not received regulatory approval, while further follow-up and potentially additional clinical studies may be needed to clarify its regulatory pathway. The report examines clinical development, regulatory milestones, launch scenarios, pricing, reimbursement, patents, generic-entry risks, competitors, SWOT analysis, licensing and corporate activity, with sales forecasts through 2034.